Taken together, these data suggest that the clinical benefit of tobramycin is due in part to an increase in the secretion of tRNA-fMet halves in OMVs, leading to attenuation of P. aeruginosa IL-8 and neutrophil-mediated CF lung damage. Here, CXCL8 is linked to cystic fibrosis.